Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Single daily dosing of aminoglycosides.
Preston SL, Briceland LL. Preston SL, et al. Pharmacotherapy. 1995 May-Jun;15(3):297-316. Pharmacotherapy. 1995. PMID: 7667165 Review.
Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.
Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL. Lodise TP, et al. Diagn Microbiol Infect Dis. 2005 May;52(1):45-52. doi: 10.1016/j.diagmicrobio.2004.12.005. Diagn Microbiol Infect Dis. 2005. PMID: 15878442 Clinical Trial.
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Drusano GL, et al. J Infect Dis. 2004 May 1;189(9):1590-7. doi: 10.1086/383320. Epub 2004 Apr 16. J Infect Dis. 2004. PMID: 15116294 Clinical Trial.
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
Preston SL, Piliero PJ, Bilello JA, Stein DS, Symonds WT, Drusano GL. Preston SL, et al. Antimicrob Agents Chemother. 2003 Nov;47(11):3393-9. doi: 10.1128/aac.47.11.3393-3399.2003. Antimicrob Agents Chemother. 2003. PMID: 14576093 Free PMC article. Clinical Trial.
Accuracy of penicillin allergy reporting.
Preston SL, Briceland LL, Lesar TS. Preston SL, et al. Am J Hosp Pharm. 1994 Jan 1;51(1):79-84. Am J Hosp Pharm. 1994. PMID: 8135263
Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia.
Preston SL, Briceland LL. Preston SL, et al. Am J Health Syst Pharm. 1995 Jan 15;52(2):164-73; quiz 205-6. doi: 10.1093/ajhp/52.2.164. Am J Health Syst Pharm. 1995. PMID: 12879543 Review.
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA. Drusano GL, et al. Antimicrob Agents Chemother. 2001 Jan;45(1):13-22. doi: 10.1128/AAC.45.1.13-22.2001. Antimicrob Agents Chemother. 2001. PMID: 11120938 Free PMC article.
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA. Drusano GL, et al. Antimicrob Agents Chemother. 2000 Jun;44(6):1655-9. doi: 10.1128/aac.44.6.1655-1659.2000. Antimicrob Agents Chemother. 2000. PMID: 10817724 Free PMC article.
76 results
Jump to page
Feedback